The purpose of this study is to evaluate an innovative approach to improving HPV vaccination among the Hispanic population. The clinical objectives/aims of this HPV educational intervention project are to determine: 1. The number of young adults and adolescents in each arm who received any dose of the HPV vaccine during the study period, 2. The number of young adults and adolescents in each arm who initiated the HPV vaccine series during the study period, 3. The number of young adults and adolescents in each arm who initiated but did not complete the HPV vaccine series during the study period, 4. The number of young adults and adolescents in each arm, among all eligible, who completed the HPV vaccine series during the study period, 5. The number of young adults and adolescents in each arm who completed the HPV vaccine series during the study period, among those who initiated the series at study start, and 6. The number of young adults and adolescents in each arm who completed the HPV vaccine series among those who initiated the series during the study period. The implementation of this educational intervention in clinic waiting rooms is intended to assist primary care providers in communicating HPV vaccine awareness and education to parents and patients in a culturally tailored format.
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period
Timeframe: 16 months
Number of Young Adults Who Initiated the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Young Adults Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Young Adults, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Young Adults Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start
Timeframe: 16 months
Number of Young Adults Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period
Timeframe: 16 months
Number of Adolescents Who Received Any Dose of the HPV Vaccine During the Study Period
Timeframe: 16 months
Number of Adolescents Who Initiated the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Adolescents Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Adolescents, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period
Timeframe: 16 months
Number of Adolescents Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start
Timeframe: 16 months
Number of Adolescents Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period
Timeframe: 16 months